GSK Jan 2025 50.000 put
| Previous close | 7.20 |
| Open | 7.20 |
| Bid | 7.30 |
| Ask | 10.70 |
| Strike | 50.00 |
| Expiry date | 2025-01-17 |
| Day's range | 7.20 - 7.20 |
| Contract range | N/A |
| Volume | |
| Open interest | 206 |
ReutersGSK whistleblower claims drugmaker cheated US government over Zantac cancer risk
(Reuters) -GSK has been sued by an independent Connecticut laboratory that accused the drugmaker of defrauding the U.S. government and taxpayers by concealing cancer risks in Zantac, once a blockbuster heartburn drug. In a whistleblower complaint filed on Monday, Valisure said GSK violated the federal False Claims Act by hiding the risks for nearly four decades while Medicare, Medicaid and other health programs covered billions of dollars of prescriptions. The New Haven-based lab said its testing in 2019 revealed that Zantac, also known as ranitidine, could form a cancer-causing carcinogen known as NMDA and was therefore "unfit for human consumption."
Evening StandardFTSE 100 Live 17 May: LandSec shares fall on results, GSK in £1.25bn final Haleon stake sale
GSK and Land Securities are in the FTSE 100 spotlight after the drugs giant sold its final Haleon shares and the property firm posted results. The sale of GSK’s remaining 4% stake raised £1.25 billion, having held 13% following its 2022 demerger of the Panadol and Sensodyne business. Land Securities revealed a smaller full-year loss of £341 million amid “robust” rental growth across its estate.
Yahoo Finance UKTrending tickers: Tesla, Reddit, Walmart and GSK
The latest investor updates on stocks that are trending on Friday.
